Skip to main content

Advertisement

SpringerLink
Log in

The use of botulinum toxins for chronic pain and headaches

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

The use of botulinum toxin in the management of various neurologic and non-neurologic disorders has grown considerably over the past decade. At the same time, new information regarding the mechanism of action of these toxins has evolved allowing for a greater understanding of the versatility of these agents. Although two types of botulinum toxin (type A Botox [Allergan, Inc., Irvine, CA] and type B Myobloc [Elan Products, New York) are commercially available in the US, most studies of the use of these toxins for the management of chronic pain and headache have been completed with type A. Data from open-label and retrospective studies as well as clinical practice suggest as strongly as possible that there is a role for these agents, especially Botox, in the management of several chronic headache disorders, including chronic migraine, chronic tension-type, cervicogenic, and cluster headache. Emerging data regarding the use of these agents for so-called “analgesic-rebound” headache also appear impressive; however, as of yet, no multicenter, randomized, controlled studies for any headache type have been published that confirm the results seen in noncontrolled studies. Nevertheless, the benefit that some patients experience from this agent is impressive, and this drug appears for many to modify the disorder in a very positive manner. In a similar fashion, data for other pain states are often restricted to open-label and case study approaches; however, clinical experience and some of the available studies (even small controlled studies) suggest a role for the toxins in the management of various chronic pain states, such as myofascial pain, low back pain, and neuropathic pain. One of the greatest challenges ahead for all interested in this area is confirming the benefit seen clinically through appropriately designed multicenter, randomized, controlled studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Settler PE: Therapeutic use of botulinum toxins: background and history. Clin J Pain 2002, 18:S19-S24.

    Article  Google Scholar 

  2. Simpson LL: Identification of the characteristics that underlie botulinum toxin potency: implications for designing novel drugs. Biochemie 2000, 82:943–953.

    Article  CAS  Google Scholar 

  3. Gobel H, Heinze A, Heinze-Kuhn K, Austermann K: Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain 2001, 91:195–199.

    Article  PubMed  CAS  Google Scholar 

  4. Guyer BM: Mechanism of botulinum toxin in the relief of chronic pain. Curr Rev Pain 1999, 3:427–431.

    PubMed  Google Scholar 

  5. Hallet M: How does botulinum toxin work? Ann Neurol 2000, 48:7–8.

    Article  Google Scholar 

  6. Cui ML, Khanijou S, Rubino J, et al.: Botulinum toxin A inhibits the inflammatory pain in the rat formalin model. Soc Neurosci Abst 2000, 26:656. Although an animal study in abstract form, this study is key in beginning to demonstrate and understand the non-cholinergic mechanisms of botulinum toxin that may be relevant in its action as an analgesic agent.

    Google Scholar 

  7. Cui M, Li Z, You S, et al.: Mechanisms of the antinociceptive effect of subcutaneous Botox: inhibition of peripheral and central nociceptive processing. Arch Pharnacol 2002, 365:33.

    Google Scholar 

  8. Evans DM, Williams RS, Shone CC, et al.: Botulinum neurotoxin type B: its purification, radio iodination, and interaction with rat brain synaptosomal membranes. Eur J Biochem 1986, 154:409–416.

    Article  PubMed  CAS  Google Scholar 

  9. Simpson LL: Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 1980, 212:16–21.

    PubMed  CAS  Google Scholar 

  10. Meunier FA, Schiavo G, Molgo J: Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol (Paris) 2002, 96:105–113.

    Article  CAS  Google Scholar 

  11. Jurasinski CV, Lieth E, Dang Do AN, et al.: Correlation of cleavage of SNAP-25 with muscle function in a rat model of botulinum neurotoxin type A induced paralysis. Toxicon 2001, 39:1309–1315.

    Article  PubMed  CAS  Google Scholar 

  12. Tsui JKC: Botulinum toxin as a therapeutic agent. Pharmacol Ther 1996, 72:13–24.

    Article  PubMed  CAS  Google Scholar 

  13. Lew MF: Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain 2002, 18:S142-S146.

    Article  PubMed  Google Scholar 

  14. Binder WJ, Brin MF, Blitzer A, et al.: Botulinum toxin type A for treatment of migraine headaches: an openlabel study. Otolgolaryngol Head Neck Surg 2000, 123:669–676.

    Article  CAS  Google Scholar 

  15. Silberstein S, Mathew N, Saper J, et al.: Botulinum toxin type A as a migraine preventive treatment. Headache 2000, 40:445–450.

    Article  PubMed  CAS  Google Scholar 

  16. Brin MF, Swope DM, O’Brien C, et al.: Botox for migraine: double blind, placebo-controlled, region-specific evaluation [abstract]. Cephalagia 2000, 20:421.

    Article  Google Scholar 

  17. Barrientos N, Chana P: Efficacy and safety of botulinum toxin type A in the prophylactic treatment of migraine. Paper presented at the American Headache Society 44th Annual Scientific Meeting. Seattle, WA; June 21–23, 2002.

  18. Eross EG, Dodick DW: The effects of botulinum toxin type A on disability in episodic and chronic migraine. Paper presented at the American Headache Society 44th Annual Scientific Meeting. Seattle, WA; June 21–23, 2002.

  19. Mathew NT, Kallasam J, Kaupp A, et al.: “Disease modification” in chronic migraine with botulinum toxin type A: long-term experience. Paper presented at the American Headache Society 44th Annual Scientific Meeting. Seattle, WA; June 21–23, 2002.

  20. Mauskop A: Long-term use of botulinum toxin type A (Botox®) in the treatment of episodic and chronic migraine headaches. Paper presented at the American Headache Society 44th Annual Scientific Meeting. Seattle, WA; June 21–23, 2002.

  21. Opida C: Open-label study of Myobloc (botulinum toxin type B) in the treatment of patients with transformed migraine headaches [abstract]. J Pain 2002, 3(suppl):10.

    Google Scholar 

  22. Freund BJ, Schwartz M: A focal dystonia model for subsets of chronic tension headache [abstract]. Cephalagia 2000, 20:433.

    Article  Google Scholar 

  23. Smuts JA, Baker MK, Wieser T, et al.: Treatment of tension-type headache using botulinum toxin type A. Eur J Neurol 1999, 6(suppl):S99-S102.

    Article  Google Scholar 

  24. Relja M: Treatment of tension-type headache by local injection of botulinum toxin. Eur J Neurol 1997, 4(suppl):S71-S73.

    Google Scholar 

  25. Wheeler AH: Botulinum toxin A, adjunctive therapy for refractory headaches associated with pericranial muscle tension. Headache 1998, 38:468–471.

    Article  PubMed  CAS  Google Scholar 

  26. Schulte-Mattler WJ, Wieser T, Zierz S: Treatment of tension-type headache with botulinum toxin: a pilot study. Eur J Med Res 1999, 4:183–186.

    PubMed  CAS  Google Scholar 

  27. Zwart JA, Bovim G, Sand T, et al.: Tension headache: botulinum toxin paralysis of temporal muscles. Headache 1994, 34:458–462.

    Article  PubMed  CAS  Google Scholar 

  28. Gobel H, Lindner V, Krack PK, et al.: Treatment of chronic tension-type headache with botulinum toxin [abstract]. Cephalagia 1999, 19:455.

    Google Scholar 

  29. Porta M: A comparative trial of botulinum toxin A and methylprednisolone for the treatment of tension-type headache. Curr Rev Pain 2000, 4:31–35.

    PubMed  CAS  Google Scholar 

  30. Ginies PR, Fraimout JL, Kong A, et al.: Treatment of cluster headache with subcutaneous injection of botulinum toxin. Paper presented at the 8th World Congress on Pain. Vancouver; August 17–22, 1996.

  31. Freund BJ, Schwartz M: The use of botulinum toxin A in the treatment of refractory cluster headache: case reports. Cephalagia 2000, 20:329–330.

    Google Scholar 

  32. Robbins L: Botulinum toxin for cluster headache. Paper presented at the 10th Congress of the International Headache Society. New York; June 29, 2001.

  33. Klapper JA, Klapper A: Use of botulinum toxin in chronic daily headaches associated with migraine. Headache Q 1999, 10:141–143.

    Google Scholar 

  34. Klapper JA, Mathew NT, Klapper A, et al.: Botulinum toxin type A (BTX-A) for the prophylaxis of chronic daily headache [abstract]. Cephalagia 2000, 20:292–293.

    Article  Google Scholar 

  35. Argoff C: Successful treatment of chronic daily headache with Myobloc [abstract]. J Pain 2002, 3(suppl):10.

    Google Scholar 

  36. Schwartz M, Freund B: Treatment of temporomandibular disorders with botulinum toxin. Clin J Pain 2002, 18:S198-S203.

    Article  PubMed  Google Scholar 

  37. Freund B, Schwartz M, Symington J: Botulinum toxin: new treatment for temporomandibular disorders. Br J Oral Maxillofac Surg 2000, 38:466–471.

    Article  PubMed  CAS  Google Scholar 

  38. Nixdorf DR, Heo G, Major PW: Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain. Pain 2002, 99:465–473.

    Article  PubMed  CAS  Google Scholar 

  39. Practical considerations for the clinical use of botulinum toxin type B: a self-study continuing medical education activity. February 2002.

  40. Wheeler A, Goolkasian P, Gretz S: Botulinum toxin A for the treatment of chronic neck pain. Pain 2001, 94:255–260. This randomized controlled study is important to recognize as it helped to identify the need for repeated injections as well as physical therapy to maximize treatment effect as well as the importance of injection technique.

    Article  PubMed  CAS  Google Scholar 

  41. Freund B, Schwartz M: Treatment of whiplash-associated neck pain with botulinum toxin A: a pilot study. Headache 2000, 40:231–236.

    Article  PubMed  CAS  Google Scholar 

  42. Cheshire WP, Abashian SW, Mann JD: Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994, 59:65–69.

    Article  PubMed  CAS  Google Scholar 

  43. Wheeler AH, Goolkasian P, Gretz SS: A randomized, double blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 1998, 23:1662–1666.

    Article  PubMed  CAS  Google Scholar 

  44. Lang A: A pilot study of botulinum toxin type A administered using a novel injection technique, for the treatment of myofascial pain. Am J Pain Manage 2000, 10:108–112.

    Google Scholar 

  45. Ferrante M, Bearn L, Rothrock R, King L: Botulinum toxin type A in the treatment of myofascial pain. Paper presented at the Annual Meeting of the American Society of Anesthesiologists. Orlando, FL; October 10, 2002.

  46. Porta M: A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 2000, 85:101–105.

    Article  PubMed  CAS  Google Scholar 

  47. Opida CL: Evaluation of Myobloc (botulinum toxin type B) in patients with post-whiplash headaches. Paper presented at the 18th Annual Meeting of the American Academy of Pain Medicine. San Francisco, CA; February 26, 2002.

  48. Taqi D, Gunyea I, Bhakta B, et al.: Botulinum toxin type A in the treatment of refractory cervicothoracic myofascial pain [abstract]. Pain 2002, 3(suppl):16.

    Google Scholar 

  49. Taqi D, Royal M, Gunyea I, et al.: Botulinum toxin type B in the treatment of refractory myofascial pain [abstract]. Pain 2002, 3(suppl):16.

    Google Scholar 

  50. Foster L, Clapp L, Erickson M, Jabbari B: Botulinum toxin A and chronic low back pain: a randomized, double blind study. Neurology 2001, 56:1290–1293. This randomized controlled study demonstrates the benefit of BTX-A injections in the treatment of chronic low back pain (even after surgery). Although performed at a single center only, the study is the first randomized study to show benefit in low back pain and should be repeated as a multicenter study in the future to confirm the results.

    PubMed  CAS  Google Scholar 

  51. Knusel B, DeGryse R, Grant M, et al.: Intramuscular injection of botulinum toxin type A in chronic low back pain associated with muscle spasm. Paper presented at the American Pain Society Annual Scientific Meeting. San Diego, CA; November 5–8, 1998.

  52. Childers MK, Wilson DJ, Gnatz SM, et al.: Botulinum toxin type A use in piriformis muscle syndrome: a pilot study. Am J Phys Med Rehabil 2002, 81:751–759.

    Article  PubMed  Google Scholar 

  53. Fannucci E, Masala S, Sodani G, et al.: CT-guided injection of botulinum toxin for percutaneous therapy of piriformis muscle syndrome with preliminary MRI results about denervation process. Eur Radiol 2001, 11:2543–2548.

    Article  Google Scholar 

  54. Fishman LM: Myobloc in the treatment of piriformis syndrome: a dose finding study. Paper presented at the 18th Annual Meeting of the American Academy of Pain Medicine. San Francisco, CA; February 26, 2002.

  55. Nalamachu S: Treatment with botulinum toxin type B injections in three patients with myofascial pain. Presented at the American Academy of Pain Medicine’s annual scientific meeting, San Francisco, CA, 2002.

  56. Smith H, Audette J, Dey R, et al.: Botulinum toxin type B for a patient with myofascial pain. Paper presented at the 18th Annual Meeting of the American Academy of Pain Medicine. San Francisco, CA; February 26, 2002.

  57. Dubin A, Smith H, Tang J: Evaluation of botulinum toxin type B injections in a patient with painful muscle spasms [abstract]. Pain 2002, 3(suppl):11.

    Google Scholar 

  58. Argoff CE: A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain 2002, 18:S177-S181.

    Article  PubMed  Google Scholar 

  59. Wissel J, Muller J, Dressnandt J, et al.: Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 2000, 20:44–49.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cohn Pain Management Center, North Shore University Hospital and New York University School of Medicine, 4300 Hempstead Turnpike, 11714, Bethpage, NY, USA

    Charles E. Argoff MD

Authors
  1. Charles E. Argoff MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Argoff, C.E. The use of botulinum toxins for chronic pain and headaches. Curr Treat Options Neurol 5, 483–492 (2003). https://doi.org/10.1007/s11940-996-0016-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-996-0016-8

Keywords

Search

Navigation